Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Antonio Zizzi
Angiogenesis Genotyping in the Selection of First-Line Treatment With Either Sunitinib or Pazopanib for Advanced Renal Cell Carcinoma
Oncotarget
Oncology
Dalbavancin and Wound Healing: New Evidences/Insights in a Mouse Model of Skin Infection.
Related publications
Pcn94 - Cost-Effectiveness of Cabozantinib Versus Sunitinib or Pazopanib as First-Line Treatment of Patients With Advanced Renal Cell Carcinoma in the Uk
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Cost-Effectiveness Analysis of Sunitinib Versus Interferon-Alfa for First-Line Treatment of Advanced and/or Metastatic Renal Cell Carcinoma in Singapore
International Journal of Technology Assessment in Health Care
Health Policy
Angiotensin Inhibitors as Treatment of Sunitinib/Pazopanib-Induced Hypertension in Metastatic Renal Cell Carcinoma
Clinical Genitourinary Cancer
Oncology
Urology
Survival Benefits of Second-Line Axitinib Versus Everolimus After First Line Sunitinib Treatment in Metastatic Renal Cell Carcinoma
Pathology and Oncology Research
Medicine
Forensic Medicine
Pathology
Oncology
Cancer Research
Sunitinib Causes Macrocytosis in Patients With Advanced Renal Cell Carcinoma
Current Oncology
Oncology
Sunitinib in the Treatment of Metastatic Renal Cell Carcinoma
Therapeutic Advances in Urology
Urology
Pharmacotherapy Options in Advanced Renal Cell Carcinoma: What Role for Pazopanib?
Clinical Medicine Insights: Oncology
Oncology
Pcn190 - Cost-Effectiveness of Nivolumab + Ipilimumab in First-Line Treatment of Advanced or Metastatic Renal Cell Carcinoma in the Netherlands
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Pazopanib Has Equivalent Anti-Tumor Effectiveness and Lower Total Costs Than Sunitinib for Treating Metastatic or Advanced Renal Cell Carcinoma: A Meta-Analysis
BMC Cancer
Cancer Research
Oncology
Genetics
